Document is current
Any future updates will be listed below
-
Authors
Solmunde, Elisabeth https://orcid.org/0000-0003-4185-1074
Pedersen, Rikke N.
Nørgaard, Mette https://orcid.org/0000-0001-6110-5891
Mellemkjær, Lene
Friis, Søren
Ejlertsen, Bent https://orcid.org/0000-0001-8761-714X
Ahern, Thomas P. https://orcid.org/0000-0003-0440-8727
Cronin-Fenton, Deirdre P. https://orcid.org/0000-0001-9738-2284
-
Funding
Funding for this research was provided by:
Aarhus Universitets Forskningsfond
Oticon Fonden
Torben og Alice Frimodts Fond
Kræftens Bekæmpelse (R336-A19239, R147-A10100, R378-A22231)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA286069, R01CA286069)
- License Information
-
More Information
Article History
Received: 16 January 2025
Revised: 19 June 2025
Accepted: 30 June 2025
First Online: 22 July 2025
Competing interests
: LM reports having an immediate family member who is employed at Novo Nordisk and an immediate family member who owns stocks in Novo Nordisk. BE reports an Advisory Role: Eli Lilly; Research funding: Institutional grants from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Novartis, Pfizer, and Seagen; and Travel, Accommodations, Expenses: Daiichi Sankyo, MSD, and Pfizer, all outside the submitted work. ES is a board member of the Danish Society of Pharmacoepidemiology, which is unrelated to the current manuscript. The Department of Clinical Epidemiology, Aarhus University, receives funding for other studies from the European Medicines Agency and from companies in the form of research grants, unrelated to the current study. All other authors have no disclosures.
: This study was based entirely on data hosted at the secure servers maintained by the Danish Health Data Authority. In accordance with Danish law, no ethics approval was required.
